← All trials
NCT04777422
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 24, 2021
- Primary completion
- Mar 31, 2024
- Completion date
- Jun 30, 2024
- First posted
- Mar 2, 2021
- Last posted
- Nov 3, 2021
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- New York Medical CollegeLead sponsor
- Johns Hopkins UniversityCollaborator
- New York UniversityCollaborator
- Columbia UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.